Akari Therapeutics Analyst Ratings
Akari Therapeutics Analyst Ratings
| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/01/2022 | 733.33% | Alliance Global Partners | → $4 | Initiates Coverage On | → Buy |
| 03/13/2020 | 941.67% | B. Riley Securities | $7 → $5 | Maintains | Buy |
| 03/29/2018 | 1566.67% | Canaccord Genuity | $15 → $8 | Maintains | Buy |
| 02/08/2018 | 525% | B. Riley Securities | → $3 | Initiates Coverage On | → Neutral |
| 日期 | 上行/下行 | 分析公司 | 目标价格变动 | 评级变动 | 之前/当前的评级 |
|---|---|---|---|---|---|
| 11/01/2022 | 733.33% | 联盟全球合作伙伴 | → 4 美元 | 启动覆盖范围开启 | → 购买 |
| 03/13/2020 | 941.67% | B. 莱利证券 | 7 美元 → 5 美元 | 维护 | 买 |
| 03/29/2018 | 1566.67% | Canaccord Genu | 15 美元 → 8 美元 | 维护 | 买 |
| 02/08/2018 | 525% | B. 莱利证券 | → 3 美元 | 启动覆盖范围开启 | → 中立 |
Akari Therapeutics Questions & Answers
Akari Therapeutics 问题与解答
The latest price target for Akari Therapeutics (NASDAQ: AKTX) was reported by Alliance Global Partners on November 1, 2022. The analyst firm set a price target for $4.00 expecting AKTX to rise to within 12 months (a possible 733.33% upside). 1 analyst firms have reported ratings in the last year.
联盟全球合作伙伴于2022年11月1日公布了Akari Therapeutics（纳斯达克股票代码：AKTX）的最新目标股价。该分析公司将目标股价定为4.00美元，预计AKTX将在12个月内升至12个月内（可能上涨733.33％）。1家分析公司去年公布了评级。
The latest analyst rating for Akari Therapeutics (NASDAQ: AKTX) was provided by Alliance Global Partners, and Akari Therapeutics initiated their buy rating.
Akari Therapeutics（纳斯达克股票代码：AKTX）的最新分析师评级由联盟全球合作伙伴提供，Akari Therapeutics启动了买入评级。
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Akari Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Akari Therapeutics was filed on November 1, 2022 so you should expect the next rating to be made available sometime around November 1, 2023.
分析师在进行了广泛的研究后得出了股票评级，其中包括浏览公开财务报表，与Akari Therapeutics的高管和客户交谈，以及听取财报电话会议。大多数分析师每三个月做一次这样的评级，因此每家公司每年应该获得4次评级。Akari Therapeutics的最新评级是在2022年11月1日公布的，因此您应该预计下一个评级将在2023年11月1日左右公布。
While ratings are subjective and will change, the latest Akari Therapeutics (AKTX) rating was a initiated with a price target of $0.00 to $4.00. The current price Akari Therapeutics (AKTX) is trading at is $0.48, which is within the analyst's predicted range.
尽管评级是主观的，并且会发生变化，但最新的Akari Therapeutics（AKTX）评级是启动的，目标股价为0.00美元至4.00美元。Akari Therapeutics（AKTX）目前的交易价格为0.48美元，在分析师的预测区间内。